EndoGastric Solutions
12
0
1
4
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 80/100
50.0%
6 terminated/withdrawn out of 12 trials
40.0%
-46.5% vs industry average
8%
1 trials in Phase 3/4
125%
5 of 4 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (12)
The Johns Hopkins Heartburn Center Registry
Role: collaborator
Multicenter Single-Blind RCT of CTIF Versus LNF For Treatment of GERD in Patients Requiring Hiatal Hernia Repair
Role: collaborator
Transoral Incisionless Fundoplication (TIF) for Laryngopharyngeal Reflux (LPR) Patients
Role: collaborator
Randomized EsophyX Versus Sham / Placebo Controlled TIF Trial: The RESPECT Study
Role: lead
Hernia Reduction Prior to Scheduled TIF Completion
Role: lead
Retrospective TIF Study for Treatment of Gastroesophageal Reflux Disease (GERD). The RetroTIF Study
Role: lead
StomaphyX Versus Sham for Revisional Surgery in Post-Roux-en-Y Patients to Reduce Regained Weight
Role: lead
The EndoGastric Solutions TEMPO Trial
Role: lead
Transoral Incisionless Fundoplication (TIF) Registry Study for Treatment of Gastroesophageal Reflux Disease (GERD)
Role: lead
Transoral Incisionless Fundoplication (TIF) Versus Sham for Treatment of Gastroesophageal Reflux Disease (GERD)
Role: lead
Endoscopic Fundoplication Versus Proton Pump Inhibitors for GERD Treatment
Role: collaborator
Registry to Compare Two Surgical Treatments for GERD
Role: collaborator
All 12 trials loaded